Table 1.
Prevalence of demographic, lifestyle, and clinical characteristics of breast cancer patients at 6 and 36 months postdiagnosis, the Shanghai Breast Cancer Survival Study (SBCSS)
| Characteristics | At 6 months postdiagnosis |
At 36 months postdiagnosis |
||||
|---|---|---|---|---|---|---|
| n = 4,842 | % | P* | n = 3,472 | % | P* | |
| Age at cancer diagnosis, years | – | – | ||||
| < 40 | 241 | 5.0 | 166 | 4.8 | ||
| 40–49 | 1,980 | 20.9 | 1,430 | 41.2 | ||
| 50–59 | 1,385 | 28.6 | 963 | 27.7 | ||
| ≥60 | 1,236 | 25.5 | < 0.01 | 913 | 26.3 | < 0.01 |
| Education | ||||||
| ≤Primary | 187 | 3.9 | 129 | 3.7 | ||
| Middle school | 390 | 8.1 | 298 | 8.6 | ||
| High school or technical training | 3,518 | 72.7 | 2,542 | 73.2 | ||
| ≥College | 744 | 15.4 | < 0.01 | 503 | 15.5 | < 0.01 |
| Monthly family income, RMB | ||||||
| < 700 | 1,379 | 28.5 | 1,031 | 29.7 | ||
| 700–999 | 1,436 | 29.7 | 1,061 | 30.5 | ||
| 1,000–1,999 | 1,459 | 30.2 | 1,006 | 29.0 | ||
| ≥2,000 | 563 | 11.6 | < 0.01 | 503 | 10.8 | < 0.01 |
| Parity | ||||||
| Nulliparous | 239 | 4.9 | 165 | 4.7 | ||
| 1 | 3,279 | 67.7 | 2,320 | 66.8 | ||
| 2 | 775 | 16.0 | 561 | 16.2 | ||
| ≥3 | 549 | 11.4 | < 0.01 | 426 | 12.3 | < 0.01 |
| Menopausal status | ||||||
| Premenopausal | 2,455 | 50.7 | 742 | 21.4 | ||
| Postmenopausal | 2,387 | 49.3 | 0.33 | 2,730 | 78.6 | < 0.01 |
| BMI, kg/m2 (mean ± SD) | 4,842 | 24.1 ± 3.4 | – | 24.5 | 24.5 ± 10.4 | – |
| Regular physical activity | 3,131 | 64.7 | < 0.01 | 2,332 | 67.2 | < 0.01 |
| Regular smoker | 130 | 2.7 | < 0.01 | 83 | 2.4 | < 0.01 |
| Regular alcohol drinker | 148 | 3.1 | < 0.01 | 97 | 2.8 | < 0.01 |
| Charlson co-morbidity index ≥1 | 968 | 20.0 | < 0.01 | 697 | 20.1 | < 0.01 |
| Total meat intake, g/d (mean ± SD) | 4,842 | 361.4 ± 183.5 | – | – | 216.4 ± 115.7 | - |
| Soy isoflavone intake, mg/d (mean ± SD) | 4,842 | 45.8 ± 38.2 | – | – | 47.6 ± 28.4 | - |
| Self-reported quality of life | ||||||
| Poor | 395 | 8.2 | 270 | 7.8 | ||
| Average | 3,543 | 73.2 | 2,563 | 73.8 | ||
| Good | 900 | 18.6 | < 0.01 | 639 | 18.4 | < 0.01 |
| Vitamin supplement user | 1,399 | 28.9 | < 0.01 | 1,056 | 30.4 | < 0.01 |
| Received surgery | 4,832 | 99.8 | < 0.01 | 3,608 | 99.9 | < 0.01 |
| Received radiotherapy | 1,556 | 32.2 | < 0.01 | 1,059 | 30.5 | < 0.01 |
| Received chemotherapy | 4,410 | 91.1 | < 0.01 | 3,160 | 91.0 | < 0.01 |
| Received immunotherapy | 709 | 14.7 | < 0.01 | 507 | 14.6 | < 0.01 |
| Tamoxifen user | 2,525 | 52.2 | 0.003 | 2,419 | 69.7 | < 0.01 |
| Stage, TNM | ||||||
| 0–I | 1,766 | 36.5 | 1,312 | 37.8 | ||
| II | 2,402 | 49.6 | 1,739 | 50.1 | ||
| III | 454 | 9.4 | 270 | 7.8 | ||
| Missing | 220 | 4.5 | < 0.01 | 151 | 4.3 | < 0.01 |
| Hormone receptor status | ||||||
| ER−/PR− | 1,330 | 27.5 | 906 | 26.1 | ||
| ER+/PR+ | 2,440 | 50.4 | 1,805 | 52.0 | ||
| ER±/PR± mixed | 979 | 20.2 | 705 | 20.3 | ||
| Missing | 93 | 1.9 | < 0.01 | 56 | 1.6 | < 0.01 |
*
Derived from t-test for continuous variables and chi-square test for categorical variables
Note: Menopausal status, BMI, tamoxifen use (cumulative), and isoflavone intake (weighted average) were calculated at both 6 and 36 months postdiagnosis
Missing data (<0.2%) was excluded from the calculations. Family history of cancer included breast and ovarian cancers